جست‌وجوی استاد و پژوهشگر

Paweł Śliwaمشاهده پروفایل

مدرس

• Computational Chemistry
• Catalysis
• Molecular Modeling
• +۳ مورد دیگر

dr inż. Paweł Śliwa is a Lecturer at the Department of Organic Chemistry and Technology , Faculty of Chemical Engineering and Technology, Tadeusz Kościuszko Cracow University of Technology. His research focuses on Computational Chemistry , Catalysis , and Molecular Modeling of receptor-ligand interactions. Institution: Tadeusz Kościuszko Cracow University of Technology Department: Organic Chemistry and Technology Rank: Lecturer Email: pawel.sliwa@pk.edu.pl Research Interests include computational catalysis, receptor pharmacology (5-HT, D4, VEGFR2), and green chemistry methods for bioactive compound extraction. His work combines quantum mechanical calculations , molecular dynamics simulations , and fragment molecular orbital analysis to investigate drug-receptor interactions and catalytic mechanisms. Publications highlight applications of computational methods in organic synthesis, receptor binding studies, and surfactant optimization for pharmaceutical/biotechnological uses. Key trends involve structure-based drug design and molecular modeling of metal complexes . Projects span from biocatalyst development (e.g., magnetic nanoparticles with immobilized catalase) to 3D-printed biomimetic scaffolds for tissue engineering. He also explores micellar extraction of plant polyphenols and halogen bonding in ligand-receptor complexes. Laboratory operates within the Computational Catalysis research team , utilizing methods like MD, FMO/PIEDA, and docking to advance understanding of molecular interactions in chemical and biological systems.

• Biophysics
• Cell Biology
• Molecular Motor Proteins
• +۳ مورد دیگر

Taro Ueda is a Professor at the Faculty of Science and Engineering, School of Advanced Science and Engineering , specializing in Biophysics and Cell Biology . With a D.Sc. from the University of Tokyo , his research focuses on actin filament regulation, molecular motor proteins, and cytoskeletal mechanics across eukaryotic systems. Major research themes include: actin-myosin interactions, cofilin dynamics, and plant-specific cytoskeletal mechanisms Key techniques employed: high-speed atomic force microscopy, fluorescence microscopy, and X-ray crystallography Research Trends from his 145+ publications (5645 citations, h-index 37) reveal consistent exploration of: Cooperative conformational changes in actin filaments Cytoskeletal specialization in plant cells (ACT2/ACT7 isoforms) Mechanical regulation of protein binding in contractile ring formation Evolution of motility systems across the Tree of Life His work has advanced understanding of Directional allostery in actin regulation Plant-specific actin nucleators like CHUP1 Nonmuscle myosin isoform differentiation Mechanisms of congenital myopathy mutations Ueda's laboratory maintains active collaborations across institutions, with notable contributions to: Development of novel actin visualization techniques (Actin Painting) Elucidating structural equilibria in G protein-coupled receptors Nanoparticle-based cancer cell destruction methods

Philip Bigginمشاهده پروفایل

استاد

• Protein Dynamics
• Drug Design
• Computational Biochemistry
• +۳ مورد دیگر

Prof Philip Biggin is a Professor of Computational Biochemistry at the University of Oxford and an Ord Fellow and Tutor at Lady Margaret Hall (LMH). He directs the DPhil in Computational Discovery Programme, having joined Oxford with a lectureship and RCUK Fellowship in 2007, becoming a Fellow and Tutor in Biochemistry in 2012 before promotion to full Professor in 2016. His research centers on protein dynamics and drug design, employing computational tools to unravel ligand-binding mechanisms and conformational changes in proteins. This work—conducted in collaboration with pharmaceutical companies—aims to enable rational drug design, leveraging local computational resources and the HECBioSim Consortium's ARCHER supercomputer. As a founder of CCPBioSim, he advances collaborative biomolecular simulation infrastructure. Recent publications demonstrate expertise in molecular dynamics simulations of ion channels, receptors, and drug-target interactions, with applications spanning neuropharmacology, toxicology, and computational method development. Key themes include nerve agent antidote design, serotonin receptor activation, and ion channel dynamics. His notable achievements include: University Excellence in Teaching Award (2011) for innovative Computational Biochemistry and Bioinformatics curricula RCUK Fellowship (2007) As Director of the DPhil programme, Prof Biggin advises graduate students while leading the Biggin Lab. His group maintains industry partnerships and contributes to major computational consortia, driving advancements in rational drug design through cutting-edge biomolecular simulation.

Bryan Rothمشاهده پروفایل

استاد

• Molecular Neuropharmacology
• GPCR Research
• Chemogenetics
• +۷ مورد دیگر

Bryan Roth, MD, PhD, is the Michael Hooker Distinguished Professor in the Department of Pharmacology at the University of North Carolina at Chapel Hill School of Medicine. He is a member of the UNC Lineberger Comprehensive Cancer Center and leads the Roth Lab, which focuses on molecular neuropharmacology and G-protein coupled receptor (GPCR) research. Dr. Roth has made significant contributions to the field through his development of the DREADD (Designer Receptor Exclusively Activated by Designer Drug) technology and receptorome profiling platform, which have revolutionized neuroscience research approaches worldwide. Dr. Roth's research spans over 30 years in molecular neuropharmacology. His laboratory pioneered the DREADD technology, which enables non-invasive remote control of neuronal signaling via orthologous ligand-receptor pairs. This innovative approach has been shared with nearly 300 labs worldwide since its introduction in 2007. Additionally, Dr. Roth developed the receptorome profiling platform, which identifies molecular targets for novel biological entities across numerous neuronal molecular targets. His work primarily focuses on GPCRs, including serotonin and opioid receptors, with applications in neuroscience, psychiatry, and drug discovery. Dr. Roth serves as the principal contractor for the National Institute of Mental Health's Psychoactive Drug Screening Program (NIMH-PDSP), through which his lab has collaborated with nearly 400 labs globally over the past 3.5 years. Analysis of Dr. Roth's recent publications reveals a strong emphasis on structural biology approaches to understanding GPCR function. His research integrates cutting-edge techniques including cryo-EM, X-ray crystallography, and computational modeling to elucidate receptor mechanisms. Key themes include DREADD technology development, psychedelic compound mechanisms, opioid receptor signaling, and the structural basis of receptor activation. His work bridges basic science with translational applications, particularly in developing novel therapeutics for neurological and psychiatric disorders, as evidenced by recent publications on non-addictive painkillers and gene therapy for chronic pain. Highly Cited Researchers (Top 1%), Web of Science, Clarivate Analytics (2020-2024) PhRMA Foundation Excellence in Pharmacology Award (2011) NARSAD Distinguished Investigator Award (2008) Michael Hooker Distinguished Professorship at UNC-Chapel Hill (2007-present) Irving Page Lecture, Serotonin Club Meeting (2010) Plenary Lecturer at Roche Pharmaceuticals Global Research (2007) Prestige Lecture at Université de Montréal (2007) As principal contractor for the NIMH Psychoactive Drug Screening Program (PDSP), Dr. Roth oversees significant research resources that serve the global scientific community. His lab maintains several important databases including the Ki Database, Tracer Database, and Anat. Profiling GPCR resources. The Roth Lab has developed innovative platforms like PRESTO-Tango and DREADDs that have transformed chemogenetic approaches in neuroscience research. Dr. Roth actively collaborates with numerous laboratories worldwide, facilitating research in GPCR pharmacology and drug discovery. His work has been featured in prominent media outlets including Nature, The New York Times, and Raleigh Magazine, highlighting the translational impact of his research on pain management and psychedelic therapeutics.

Matthew R. Redinboمشاهده پروفایل

استاد

• Molecular Biology
• Biochemistry
• Microbiome Research
• +۸ مورد دیگر

Matthew R. Redinbo is a Professor at the University of North Carolina at Chapel Hill School of Medicine , holding the William R. Kenan Distinguished Professor chair in the Department of Chemistry. His research bridges structural biology, microbiology, and drug development to address human health challenges. Research Focus: • Molecular basis of human disease : Explores mechanisms of drug metabolism, nuclear receptors, and antibiotic resistance • Gut microbiome : Develops activity-based probe-enabled proteomics pipelines for enzyme quantification in human feces • Therapeutics discovery : Uses structural and chemical biology to design enzyme inhibitors Key Techniques: • Protein crystallography • Pharmacokinetic (PK) studies • Next-gen "omics" technologies (microbial sequencing, metabolomics) Scientific Awards: Pilot and Feasibility Award (2008), Center for Gastrointestinal Biology and Disease Article Trends: Recent work emphasizes gut microbiome dynamics (bile acid metabolism, estrobolome), host-microbe interactions (PXR/TLR4 signaling), and structure-guided drug design (CHD1 antagonists, uremic toxin mitigation). Collaborations: Works with researchers across microbiology, pharmacology, and clinical medicine (Azcarate, Bhatt, Fodor, Gulati, Rawls, Sartor, Theriot). Leads projects integrating basic science with translational applications in murine models.

Peter W. Hildebrandمشاهده پروفایل

استاد

• Structural biology
• Molecular dynamics
• G protein-coupled receptors (GPCRs)
• +۳ مورد دیگر

Peter W. Hildebrand is a Professor at the University of Leipzig , leading the Proteinformatics Workgroup in the Department of Protein Formatics . His research focuses on GPCR structural dynamics and computational biophysics , using molecular dynamics simulations and bioinformatics to study membrane protein interactions. His workgroup develops interactive web tools like MDsrv for simulation analysis, MutationExplorer for mutation visualization, and ProteinPrompt for interaction prediction. Recent publications highlight collaborations on GPCR activation mechanisms , ligand binding , and adhesion GPCR functional dynamics . Scientific contributions include developing methods for fragment-based protein modeling , conformational pathway analysis , and allosteric modulation studies . He mentors doctoral candidates like Maik Pankonin and Maximilian Salomon , while maintaining active collaborations in computational structural biology and transmembrane signaling research .

Eckhard Schulzمشاهده پروفایل

استاد

• Mathematical Modeling
• Ion Channels
• Biophysics
• +۴ مورد دیگر

Professor Eckhard Schulz is a faculty member in the Faculty of Electrical Engineering at Schmalkalden University of Applied Sciences, where he focuses on the intersection of mathematics, physics, and biological systems. His office is located in House B, Room 0412, and he can be reached at +49 3683 688 5100. Professor Schulz's research centers on the mathematical modeling of ion channels, with particular emphasis on understanding the thermodynamics and kinetics of channel gating mechanisms. His work explores subunit cooperativity in multimeric channels, equilibrium constants for receptors with multiple binding sites, and the application of Markov models to describe complex ion channel behavior. This research bridges physics, mathematics, and biology to unravel fundamental mechanisms underlying cellular electrical signaling. His publication record spans nearly two decades, with consistent output in high-impact journals including PNAS, Nature Communications, and Journal of General Physiology. Recent work (2022-2023) continues his long-standing research focus while addressing increasingly complex models of ion channel behavior. His articles demonstrate sophisticated mathematical approaches to understanding biological phenomena, with particular attention to the thermodynamic profiles of receptor-channel systems. Professor Schulz maintains active research collaborations, most notably with Klaus Benndorf and other researchers in the biophysics community. His work represents an important contribution to the field of computational biophysics, providing theoretical frameworks that help interpret experimental data on ion channel function. Students interested in mathematical biology or computational neuroscience would find valuable research opportunities in his group, working at the intersection of theoretical modeling and biological application. His research has practical implications for understanding channelopathies and potentially developing more targeted pharmaceutical interventions that could modulate specific aspects of ion channel behavior, demonstrating the real-world impact of his theoretical work.

Min Luمشاهده پروفایل

دانشیار

• Membrane Transport Proteins
• X-ray Crystallography
• Structural Biology
• +۳ مورد دیگر

Min Lu is an Associate Professor in the Department of Biochemistry and Molecular Biology at Rosalind Franklin University's Chicago Medical School, where she leads structural biology research on membrane transport proteins. She is affiliated with the Center for Proteomics and Molecular Therapeutics and maintains active collaborations across the university's research ecosystem. Her academic background includes: PhD in Molecular Biophysics and Biochemistry from Yale University (2001) Research Fellowship at Memorial Sloan-Kettering Cancer Center (2002-2004) Research Associate position at Brookhaven National Laboratory (2005-2008) Dr. Lu's research program centers on X-ray crystallography of membrane transport proteins, with dual focus on bacterial nutrient transporters and human MATE transporters implicated in drug resistance. Her NIH-funded work on MATE transporters aims to elucidate structural mechanisms of multidrug efflux to develop resistance-countering strategies. The lab's publication record demonstrates expertise in solving challenging membrane protein structures, including those with crystallographic complications like anisotropy and twinning. Current funding supports active recruitment of graduate students and postdoctoral fellows, with emphasis on candidates possessing membrane protein purification skills. The lab leverages proximity to Argonne National Laboratory's Advanced Photon Source for cutting-edge structural studies. Dr. Lu's research bridges fundamental structural biology and therapeutic applications, particularly in overcoming antimicrobial and chemotherapy resistance through mechanistic understanding of transporter proteins.

Alice Guyonمشاهده پروفایل

استاد پژوهشی

• Neuroscience
• Neuroendocrinology
• Integrative Medicine
• +۴ مورد دیگر

Alice Guyon is a Research Director at the Centre de Recherche en Psychologie et Neurosciences (CRPN), part of Aix Marseille Université and affiliated with CNRS. She joined CRPN in August 2023 and since January 2024 has served as Publication Director for the Integrative Health journal HEGEL (CAIRN). Her research spans neuroscience, neuroendocrinology, and integrative medicine with a focus on mind-body practices and non-ordinary states of consciousness. Dr. Guyon's research interests focus on the effects of non-ordinary states of consciousness (Mindfulness Meditation, Meditative Relaxation, Self-Hypnosis and Self-Induced Cognitive Trance) on memory in relation to emotional valence (with potential applications to post-traumatic stress disorder and depression), teachers' voice and stress reduction, and quality of life for patients with multiple sclerosis. Her work bridges traditional neuroscience with integrative medicine approaches, particularly examining how mind-body practices like Tai Chi, Yoga, and Qi-gong affect physical and mental health. She has published extensively on chemokines, neuroinflammation, adiponectin signaling, and the neurobiological mechanisms underlying enriched environments and their effects on brain plasticity. Her recent publications demonstrate a clear evolution from basic neuroscience research on chemokines, melanin-concentrating hormone, and neuroinflammation toward more integrative approaches examining mind-body practices and their physiological mechanisms. This trajectory reflects a growing interest in translating basic neuroscientific findings into practical applications for mental health and wellness. Her work on Tai Chi, Yoga, and other mind-body practices represents an effort to establish scientific validation for these traditional practices while exploring their underlying physiological mechanisms. Dr. Guyon has served as Publication Director for the Integrative Health journal HEGEL since January 2024, demonstrating leadership in her field. While specific grant information isn't detailed in the available text, her extensive publication record across multiple disciplines suggests successful funding for her research activities. Her collaborative approach is evident in her numerous co-authored publications across neuroscience, immunology, and integrative medicine domains. Her research appears to be conducted through the Centre de Recherche en Psychologie et Neurosciences (CRPN), where she leads projects examining the intersection of psychological states, consciousness, and physiological outcomes. Her work often involves interdisciplinary teams bringing together expertise from neuroscience, psychology, immunology, and complementary medicine fields to investigate the mind-body connection from multiple angles.

• Biomedical Imaging
• Nuclear Medicine
• Neuroscience
• +۳ مورد دیگر

Marc David Normandin is an Associate Professor of Radiology and Biomedical Imaging at Yale School of Medicine, where he serves as Director of the Yale PET Core. He is affiliated with the Bioimaging Sciences Center, Center for Molecular Imaging Technology and Translation (CMITT), and Yale Biomedical Imaging Institute. His research focuses on advanced PET imaging techniques for neurodegenerative diseases and psychiatric disorders, with expertise in kinetic modeling, radioligand development, and multimodal neuroimaging. He collaborates extensively with Georges El Fakhri, Nicolas Guehl, and other researchers across 84 publications. Recent publications highlight innovations in tau burden quantification, 5D proton therapy delivery for cardiac arrhythmias, and receptor occupancy mapping with novel radiotracers. His work bridges biomedical engineering and clinical applications in nuclear medicine. Normandin holds a PhD in Biomedical Engineering from Purdue University (2008) and completed postdoctoral training at Yale School of Medicine (2011). He maintains contact via marc.normandin@yale.edu and office number 203.737.4803.

Ken Pearceمشاهده پروفایل

استاد پژوهشی

• Early drug discovery
• Oncology
• Epigenetic targets
• +۴ مورد دیگر

Ken Pearce is a Research Professor at the UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill. He leads an interdisciplinary team focused on early-stage drug discovery, particularly in oncology and epigenetic pathways. Education: No explicit educational details are provided in the text. Research Interests: His laboratory integrates reagent production, assay development, high-throughput screening, biophysics, and exploratory cell biology to identify small-molecule chemical probes and therapeutics. Specific areas include inhibition of chromatin methyl-lysine reader proteins, targeting small GTPases (e.g., K-Ras, Gaq), inositol phosphate kinases, and protein–protein interactions involving CIB1 and MAGE proteins. They also pursue phenotypic screens—such as enhancing c-Myc degradation in pancreatic cancer cells—and are advancing DNA-encoded library technologies as a complement to traditional high-throughput approaches. Publication Trends: Recent articles (2022–2025) emphasize chemical biology, structure-guided drug design, epigenetic modulators, and immunotherapy. Earlier work (2004) focused on structural characterization of nuclear receptors. The trajectory illustrates a consistent focus on translating biochemical insights into therapeutic leads for cancer, neurodegeneration, and inflammatory diseases. Funding & Collaborations: Pearce actively partners with the Center for Integrative Chemical Biology and Drug Discovery and multiple groups across the UNC campus, leveraging shared resources and expertise to accelerate translational research. Laboratory & Teams: He directs a comprehensive collaborative group housed in Marsico Hall, Chapel Hill, NC, equipped for high-throughput screening, biophysical characterization, and cellular imaging.

Ayman Khattabمشاهده پروفایل

استاد مدعو

• Malaria Research
• Parasitology
• Vector Biology
• +۳ مورد دیگر

Ayman Khattab is an Adjunct Professor of Parasitology at the University of Helsinki, specializing in malaria research for over 20 years. He established a malaria research lab at the University of Helsinki in 2007, focusing on Plasmodium falciparum and Anopheles mosquitoes. His roles include Principal Investigator and supervisor in multiple doctoral programs, including Biomedicine and Population Health. Research interests center on malaria pathogenesis and control strategies: Novel mosquito vector control methods using 3D screen technology Immune interactions between mosquitoes and human hosts Complement system evasion by P. falciparum Surface antigens as virulence factors in malaria parasites His work integrates immunology, parasitology, and tropical medicine, with recent publications analyzing complement inhibitors, vaccine delivery systems, and sustainable mosquito control. Research spans both laboratory and field studies, particularly in Tanzania.

Joseph Salvinoمشاهده پروفایل

استاد

• Drug Discovery and Development
• Medicinal Chemistry
• Small Molecule Lead Compounds
• +۷ مورد دیگر

Joseph Salvino, Ph.D. is a Professor in the Molecular and Cellular Oncogenesis Program at The Wistar Institute's Ellen and Ronald Caplan Cancer Center. He serves as Scientific Director of the Molecular Screening & Protein Expression Facility. As the first medicinal chemist to join Wistar's staff, Salvino brings over 30 years of experience in drug discovery, including hit-to-lead development, lead optimization, and preclinical development where several drug candidates have successfully completed human clinical trials. Ph.D. in Organic Chemistry, Brown University Postdoctoral Training in Synthetic and Medicinal Chemistry, University of Pennsylvania (mentored by K.C. Nicolaou and Ralph F. Hirschmann) Former Professor, Department of Pharmacology and Physiology, Drexel University College of Medicine Prior Industry Experience: Sterling Winthrop, Rhone-Poulenc Rorer, Aventis, Rib-X Pharmaceuticals, Adolor Corporation, and Cephalon Salvino's research focuses on drug discovery and development, with laboratory work centered on early drug discovery and small molecule tool compounds for in vivo target validation. His medicinal chemistry optimization work focuses on designing new chemical analogs to understand structure-activity relationships critical for optimizing potency and efficacy. Current research projects include compounds blocking HIV and other antivirals, glutamate transporter (EAAT2) stimulators, ACSS2 Inhibitors, PROTACs targeting CDK6, Mdm2, and Tert, small molecules targeting protein-protein interactions, and cancer/gram-negative bacteria targeting pro-drugs. Analysis of Salvino's recent publications reveals a strong focus on cancer therapeutics, particularly targeting metabolic pathways and protein degradation mechanisms. His work spans multiple cancer types including breast cancer, pancreatic cancer, leukemia, and melanoma. The research demonstrates expertise in medicinal chemistry, target validation, and development of novel therapeutic approaches such as PROTACs and transition-state mimetics. Salvino leads an active research laboratory with several postdoctoral fellows including Adi Narayana Reddy Poli, Jitendra Gour, and Nitesh Nandwana. His research is supported by multiple NIH grants (S10OD030245 and P30CA010815), Canadian Institutes of Health Research grant (CIHR PJT-153057), and Commonwealth of Pennsylvania Special Initiatives Grant for COVID-19 research. As Scientific Director of the Molecular Screening & Protein Expression Shared Resource, Salvino oversees facilities that closely align with the lead optimization and hit-to-lead activities ongoing in his laboratory. His recent work on SARS-CoV-2 Mpro inhibitors demonstrates the lab's ability to rapidly respond to emerging health threats through innovative drug discovery approaches.

• Neurotransmitter transporters
• Glutamate receptors
• Molecular pharmacology
• +۴ مورد دیگر

Anders Skov Kristensen is an Associate Professor in the Department of Drug Design and Pharmacology at the University of Copenhagen's Faculty of Health and Medical Sciences. His research focuses on molecular and cellular pharmacology, with special emphasis on neurotransmitter transporters and glutamate receptors. Dr. Kristensen's research interests span multiple areas of molecular pharmacology: Structural biology of neurotransmitter receptors Mechanisms of serotonin and glutamate transporters Allosteric modulation of kainate receptors Development of novel receptor antagonists and modulators Molecular basis of antidepressant drug action Neurotransmitter receptor structure-function relationships His recent publications demonstrate a strong trend toward structural characterization of receptor-ligand interactions, particularly for kainate receptors and the serotonin transporter. Using advanced techniques like X-ray crystallography, fluorescence imaging, and molecular modeling, his work provides critical insights into receptor activation mechanisms and the structural determinants of drug efficacy across multiple receptor systems. With an extensive publication record of 79 research outputs and numerous conference presentations, Dr. Kristensen has established himself as a significant contributor to the field of molecular pharmacology. His research has implications for developing novel therapeutics targeting neurological and psychiatric disorders.

• Structural Biology
• Pharmacology
• X-ray Crystallography
• +۵ مورد دیگر

Karla Andrea Frydenvang is an Associate Professor in the Department of Drug Design and Pharmacology at the Faculty of Health and Medical Sciences, University of Copenhagen. With a career spanning over three decades since earning her PhD in 1989, she has established herself as a leading researcher in structural pharmacology and neuropharmacology. Current Position: Associate Professor (2002-present) Previous Appointments: Assistant Professor (1989-1990), Research Fellowships (1990-2002) Education: Cand. pharm. (1985), PhD pharm. (1989) from Royal Danish School of Pharmacy Dr. Frydenvang's research focuses on membrane-bound ionotropic glutamate receptors, particularly examining the extracellular ligand-binding domain expressed from E. coli. Her work analyzes protein complexes with various ligands to understand binding affinity, selectivity, and specificity through X-ray crystallographic studies. This structural approach has yielded significant insights into receptor function and modulation. Her recent publications (2022-2024) demonstrate a strong focus on glutamate receptor pharmacology, particularly AMPA and kainate receptors, with several papers examining positive allosteric modulators. Additional research areas include AKR1C3 inhibitors for prostate cancer and serotonin receptor agonists, showing the breadth of her structural pharmacology expertise. The publications reveal a consistent pattern of structural biology approaches applied to neuropharmacology and cancer drug development. Alfred Benzon Research Fellowship (1994-1997) Bøje Benzon Research Fellowship (1999-2002) Member of the Danish National Committee for Crystallographers since 1999 As an educator, Dr. Frydenvang participates in teaching pharmacy students through lectures, seminars, and practical courses in organic chemistry and philosophy of science. She has contributed to developing specialized courses including 'Structural and Computational Medicinal Chemistry' and 'Medicines: Design, Development, Delivery and Use.' Her mentorship extends to advising master's students and serving as advisor and external examiner for PhD candidates. Her leadership roles include chairing the department's teaching committee from 2009-2012.